Please login to the form below

Not currently logged in
Email:
Password:

MSL Group media exec joins GCI

Becky Lauer, senior vice president and director of broadcast media/global health at MSL Group, has joined GCI Health to serve as senior vice president, director of media

Becky Lauer, who spent the past 11 years at MSL Group as senior vice president and director of broadcast media/global health, has joined GCI Health to serve as senior vice president, director of media.

In her new role, she will be responsible for providing strategic counsel and support across all GCI Health's account teams; planning and assessing media strategies; and creating media angles to reach specific target audiences.

During her time at MSL Group, Lauer provided strategic media counsel and generated media placements for healthcare clients including Pfizer, Roche, Merck, Eli Lilly, Abbott, Bayer, Novartis, sanofi-aventis, Johnson & Johnson, Daiichi-Sankyo and Genentech.

She was responsible for media relations for all FDA hearings/approvals and crisis management for MSL's healthcare practice.

Before moving to the agency side and joining MSL, Lauer spent two decades as a producer in the US for CNN, Fox News and CBS Evening News with Dan Rather.

Lauer's move comes a week after MSLGroup hired Ogilvy's David Bashaw to serve as senior vice president, deputy healthcare practice director, MSL New York.

New York City-based GCI Health is WPP's only healthcare public relations company. It was formed in 2008 when WPP merged Cohn & Wolfe and GCI Group, bringing both agencies together under the C&W name and breaking out GCI Health as a separate global healthcare agency.

GCI Health serves healthcare companies such as Johnson & Johnson, Eli Lilly, Genentech and Merck in addition to hospitals, not-for-profit organisations and other institutions.

31st May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics